NEW YORK, April 29, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Enzon Pharmaceuticals, Inc. (NASDAQ: ENZN), Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX), iBiO Inc. (NYSEMKT: IBIO), and Perrigo Company Plc (NYSE: PRGO). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
ENZN Research Report: ( http://get.analystsreview.com/pdf/?c=Enzon&d=29-Apr-2015&s=ENZN ),
AERI Research Report: ( http://get.analystsreview.com/pdf/?c=Aerie%20Pharmaceuticals&d=29-Apr-2015&s=AERI ),
CPRX Research Report: ( http://get.analystsreview.com/pdf/?c=Catalyst%20Pharma&d=29-Apr-2015&s=CPRX ),
IBIO Research Report: ( http://get.analystsreview.com/pdf/?c=iBiO%20Inc.&d=29-Apr-2015&s=IBIO ),
PRGO Research Report: ( http://get.analystsreview.com/pdf/?c=Perrigo%20Company&d=29-Apr-2015&s=PRGO ).
Analyst Update: Clinical Trial Results, Patent Updates, and Unsolicited Offers
Reviewed by: Rohit Tuli, CFA®
U.S. stocks closed mixed on Tuesday as investors remained vigil over tech earnings and the Federal Reserve's concluding statement on Wednesday. The Dow Jones Industrial Average advanced 0.40%, to close the day at 18,110.14, and the S&P 500 gained 0.28%, to 2,114.76. However, the NASDAQ Composite was down 0.10%, to finish the session at 5,055.42. European stocks tumbled on Tuesday amid concerns over Federal Reserve's meeting outcome. Germany's DAX 30 fell 1.89%, France's CAC 40 lost 1.81%, and London's FTSE 100 ended 1.03% lower on Tuesday. Meanwhile, Asian stock markets mostly closed lower on Tuesday. The Shanghai Composite Index and Australia's S&P ASX both fell on Tuesday, while Hong Kong's Hang Seng index was flat.
On April 21, 2015, TheStreet.com came out with a report on Enzon Pharmaceuticals. According to the report, TheStreet Quant Ratings rates Enzon as a "Hold".
On April 23, 2015, Aerie Pharmaceuticals, Inc. reported the results of its first Phase 3 registration trial (Rocket 1) for RhopressaTM, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The Company informed that the trial did not meet its primary efficacy endpoint of demonstrating non-inferiority of IOP lowering for once-daily RhopressaTM compared to twice-daily Timolol, the most widely used competitor drug in registration trials for glaucoma.
On April 24, 2015, TheStreet.com reported that Catalyst Pharmaceutical Partners' plan of seeking approval and marketing of a drug for a rare muscle-wasting disease called Lambert-Eaton Myasthenic Syndrome (LEMS) is in the doldrums following a surprise disclosure of positive clinical trials from a competitor drug.
iBio Inc. announced on March 30, 2015 that it has received a notice from the European Patent Office which states that the opposition period expired for a bio-defense product patent granted to iBio, and no opposition was filed.
On April 24, 2015, Perrigo Company plc announced its rejection of the unsolicited offer from Mylan NV to acquire all of the outstanding shares of Perrigo for $60.00 per share in cash and 2.2 Mylan ordinary shares for each ordinary Perrigo share (the "Offer").
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review